The pharmaceutical world is seeing a major shift in diabetes management with the introduction of GLP-1 transdermal devices. These patches offer a possibly more convenient alternative to subcutaneous administrations of GLP-1 drugs, minimizing the need for daily needle pricks. The technology releases the drug directly through the surface, possibly en